Surveillance After Mantle-Field Radiation for Hodgkin Lymphoma

She is a chest-radiation survivor and is at substantially elevated breast cancer risk. Mantle-field radiation at 36 Gy before age 30 is exactly the exposure that drives the recommendation.

Guideline-concordant surveillance:

• Annual mammography PLUS annual breast MRI, starting at age 25 or 8 years after radiation, whichever is later, and continuing long-term (survivorship guidelines do not set an upper stopping age - many continue indefinitely).
• For her: 16 + 8 = 24, but the floor is age 25, so screening should have begun at 25. She is 46 - that is roughly two decades of indicated screening, and the key question in clinic is whether it has actually been happening.
• Practically, alternating mammogram and MRI every 6 months reduces the burden of same-day imaging and improves adherence.

Why both modalities: MRI has higher sensitivity in young women and in radiation-affected breast tissue; mammography adds specificity and detects calcifications and ductal carcinoma in situ. Neither alone is adequate in this population.

What to do today: verify the actual screening history rather than assuming. If she has never been screened, that is the single highest-yield intervention in this visit - far more valuable than any of the tests she asked about. If she has been screened, ask about the interval and about any abnormal results lost to follow-up.

Do not do: routine breast self-exam teaching as a substitute, and do not accept "she had a normal mammogram last year" as complete - the MRI is the missing piece in most under-screened survivors.

CA-125 with transvaginal ultrasound - no. She has no known pathogenic variant and no family history given here to justify it. More importantly, in average-risk and even modestly elevated-risk women, ovarian cancer screening with CA-125 and ultrasound has not been shown to reduce mortality and generates false positives that lead to surgery. Offering it because she asked would be a well-intentioned harm. If she develops persistent bloating, early satiety, pelvic pain, or urinary urgency, that warrants diagnostic evaluation - not annual screening.

Whole-body MRI - no. There is no evidence that it improves outcomes in asymptomatic Hodgkin survivors. It has a high rate of incidental findings that trigger further imaging, biopsy, and anxiety. Survivors who have had a lot of imaging are the population least able to absorb that cascade.

Annual chest CT - no, not as screening. She is a lifelong nonsmoker and does not meet lung cancer screening criteria (screening is for adults 50–80 with ≥20 pack-years, current or quit within 15 years). She is at somewhat increased lung cancer risk from mantle radiation, but there is no validated annual CT screening strategy for radiation-exposed never-smokers - and annual CT over decades in a 46-year-old carries a real cumulative radiation dose.

What she should be offered instead - and this is the point of the visit:

• Echocardiogram for baseline cardiac function (chest radiation is cardiotoxic: valves, coronaries, pericardium), plus blood pressure and lipid management - she is already hypertensive.
• TSH annually - she has established radiation-induced hypothyroidism; confirm dosing is adequate. Thyroid ultrasound only if a nodule is palpated, not routinely.
• Carotid evaluation as a shared decision with cardiology if she has symptoms or bruits; routine carotid ultrasound after neck radiation is debated, not standard.
• Counseling about secondary malignancy - breast, thyroid, sarcoma in the radiation field, and lung - with instructions to report a new lump, bone pain, or persistent hoarseness rather than waiting for a scan.

Say the reasoning out loud. She is asking for tests because she is afraid, and "no" without a rationale feels like abandonment. Explain that you are declining tests that do not work and offering tests that do.

Highest-risk gap: cardiovascular risk, not cancer. She is 46, hypertensive, with a BMI of 31, and 36 Gy to the mediastinum including the coronary ostia and valves. Radiation-associated coronary disease presents earlier and more often without typical angina than in the general population. The mortality threat here is at least as likely to be cardiac as recurrent Hodgkin lymphoma.

What belongs in the visit:

• Cardiac risk assessment: baseline echocardiogram, fasting lipids, HbA1c, blood pressure to target, and a low threshold for stress testing or coronary imaging if she has any exertional symptoms. Consider cardiology co-management given the radiation dose and field.
• A written survivorship care plan sent to her primary care clinician, specifying the radiation field and dose, the screening schedule (annual mammogram + MRI), the cardiac surveillance plan, and the fact that she should not be enrolled in generic "average-risk" screening pathways.
• Reproductive and bone health: her fertility status and, if she is postmenopausal or becomes so, bone density given hypothyroidism and possible hormone changes. Ask about sexual health - rarely raised and frequently important.
• Psychosocial screening: survivors of adolescent cancer carry elevated rates of anxiety, depression, and fear of recurrence. She has not been asked; ask.
• Insurance and employment: mantle radiation at 16 may complicate coverage and life insurance. This is a coordination-of-care issue, not a soft one.
• Vaccinations and general preventive care - she should not fall through the primary care gap because she is "managed by oncology."

Why this matters conceptually. The exam-relevant judgment is that survivorship is not a screening checklist. The right response to "what screening do I need" is to identify which interventions have evidence (breast MRI, cardiac risk management, TSH), which have none (whole-body MRI, ovarian screening), and which are gaps in the system rather than in the patient (no care plan, no cardiology, no one tracking her).